公开(公告)号：US20220106307A1

公开(公告)日：2022-04-07

申请号：US17398478

申请日：2021-08-10

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Hwan Geun CHOI ,  Eunhwa KO ,  Joong-heui CHO ,  Jung Beom SON ,  Yi Kyung KO ,  Jin-Hee PARK ,  So Young KIM ,  Seock Yong KANG ,  Seungyeon LEE ,  Hee Yoon RYU ,  Nam Doo KIM ,  Sang Bum KIM ,  Sun-Hwa LEE ,  Dayea KIM ,  Sun Joo LEE ,  Sungchan CHO ,  Kyu-Sun LEE ,  Kweon YU ,  Miri CHOI ,  Ja Wook KOO ,  Hyang-Sook HOE

IPC分类号： C07D471/04 ,  A61P25/28

摘要： The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.

公开(公告)号：US20200207756A1

公开(公告)日：2020-07-02

申请号：US16495455

申请日：2018-03-23

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY ,  DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Hwan Geun CHOI ,  Eunhwa KO ,  Joong-heui CHO ,  Jung Beom SON ,  Yi Kyung KO ,  Jin-Hee PARK ,  So Young KIM ,  Seock Yong KANG ,  Seungyeon LEE ,  Hee Yoon RYU ,  Nam Doo KIM ,  Sang Bum KIM ,  Sun-Hwa LEE ,  Dayea KIM ,  Sun Joo LEE ,  Sungchan CHO ,  Kyu-Sun LEE ,  Kweon YU ,  Miri CHOI ,  Ja Wook KOO ,  Hyang-Sook HOE

IPC分类号： C07D471/04 ,  A61P25/28

摘要： The present invention relates to a pyrrolopyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.

公开(公告)号：US20200239474A1

公开(公告)日：2020-07-30

申请号：US16488194

申请日：2018-02-22

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  NATIONAL CANCER CENTER ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

发明人： Hwan Geun CHOI ,  Jong Bae PARK ,  Eunhwa KO ,  Jung Beom SON ,  Joong-heui CHO ,  Yi Kyung KO ,  Jin-Hee PARK ,  So Young KIM ,  Seock Yong KANG ,  Seungyeon LEE ,  Nam Doo KIM ,  Yunho LEE ,  Sun-Hwa LEE ,  Dayea KIM ,  Sun Joo LEE ,  Jae Hyun BAE ,  Eunmi HONG ,  Tae-ho JANG ,  Sang Bum KIM ,  Seung Hoon LEE ,  Do-Hyun NAM

IPC分类号： C07D487/04

摘要： The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases.

公开(公告)号：US20230142654A1

公开(公告)日：2023-05-11

申请号：US17788440

申请日：2021-01-15

申请人： DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION ,  PIMEDBIO, INC.

发明人： Chun Young IM ,  Sang Hyun MIN ,  Ji Hoon YU ,  Eun Bi KO ,  So Young KIM ,  Seungyeon LEE ,  Dong Kyu CHOI ,  Heejin LEE ,  Ga Young PARK ,  Doohyun LEE ,  Eunmi HONG ,  Hui-Jeon JEON ,  Young-Hoon PARK ,  Ye Ri HAN ,  Nam Hui KIM ,  Jun Woo KIM ,  Bae Jun OH ,  Jeong-Eun PARK ,  Chang Hoon SEO ,  Minsoo SONG ,  Seonggu RO ,  Dongkyu SHIN

IPC分类号： C07C311/29 ,  C07D295/12 ,  C07D295/14 ,  C07D211/10 ,  C07D207/27 ,  C07D209/16 ,  C07D209/14 ,  C07D235/14 ,  C07D235/06 ,  C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D471/04 ,  C07D209/86

CPC分类号： C07C311/29 ,  C07D295/12 ,  C07D295/14 ,  C07D211/10 ,  C07D207/27 ,  C07D209/16 ,  C07D209/14 ,  C07D235/14 ,  C07D235/06 ,  C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D471/04 ,  C07D209/86

摘要： The present invention relates to a method for preparing a biomaterial having selectively functionalized tyrosine, a biomaterial having selectively functionalized tyrosine, and a pharmaceutical composition containing the same as an active ingredient. The method for preparing a biomaterial to which a compound represented by formula 2 is coupled, of the present invention, allows the compound represented by formula 2 to be selectively coupled, in a high yield in a biomaterial, to tyrosine, which is present on the surface of an aqueous solution such that the coupling thereof to amino acids other than tyrosine does not occur and, when only one tyrosine is present, heterogeneous mixtures are not present and the inherent activity of the biomaterial is maintained, and thus the compound can be effectively used as a pharmaceutical composition containing a biomaterial drug as an active ingredient. In addition, the method can selectively functionalize tyrosine, and thus can be effectively used for tyrosine functionalization in a biomaterial.